跳至主要内容
临床试验/NCT02970175
NCT02970175已完成3 期

Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy

University Hospital, Rouen1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2017年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
130
试验地点
1
主要终点
Number of biopsy realized during the endoscopy

研究概览

简要总结

The diagnostic yield of flexible bronchoscopy for the diagnosis of lung cancer depends on the location and the histological type of the lesion, as well as on the number of biopsy samples performed. The increasing number of sampling is also important to provide material for molecular assessment of lung cancer. The French National Institute for Cancer recommends a number of 5 biopsies in order to reach a diagnostic yield of 88%. However, as increasing the number of bronchial biopsies comes with a higher risk of bleeding, the management of endobronchial bleeding may be determinant for the diagnostic yield.

The most recent recommendations of the British Thoracic Society for the management of bronchial bleeding, after bronchial or transbronchial biopsy, are to inject 5 to 10 mL of 1/10000 diluted adrenalin, or cold saline serum (04°C.). The French guidelines also include the use of endobronchial terlipressin, which has local vasoconstriction effect. After endobronchial administration of terlipressin, plasmatic concentrations are low, and are not clinically relevant.

The hypothesis of this clinical trial is that endobronchial instillation of terlipressin before sampling endobronchial tumor will limit the endobronchial bleeding and allow to increase the number of biopsies performed and, eventually, the diagnostic yield.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥18 years old
  • Patients scheduled to undergo bronchoscopy, presenting a suspicious radiographic lesion and a lesion proximal tumor pace viewable in white light endoscopy and without pathologic diagnosis
  • Patient having read and understood the information letter and signed the consent form
  • Effective contraception in women of childbearing age

排除标准

  • Patients with contraindication to the use of terlipressin:
  • septic shock ,
  • Hypersensitivity to terlipressin or the excipients or by whom use the product is not recommended:
  • Recent history (<3 months) of acute coronary syndrome (including myocardial infarction) or unbalanced coronary insufficiency, or disorders of the ventricular heart rate.
  • severe uncontrolled hypertension,
  • cerebrovascular insufficiency and ischemic stroke of recent origin (<3 months).
  • severe arterial occlusive lower extremities,
  • severe chronic renal impairment (GFR <20 ml / min).
  • Patients receiving uninterrupted antiplatelet therapy during 5 days before endoscopy (7 days for Clopidogrel Related), including low dose aspirin (≤ 75 mg / day).
  • Patients receiving anticoagulant therapy:
  • Unfractionated heparin within 12 hours before endoscopy.
  • low molecular weight heparin within 24 hours before endoscopy.
  • Patients with bleeding disorders defined by TP below 70% or TCA ratio patient / control greater than 1.
  • Patients with thrombocytopenia less than 100 g / L.
  • Subjects misunderstanding of spoken and written French
  • Person under guardianship or deprived of liberty by judicial or administrative decision (under Article L1121-6 and L1121-8 of Public Health Code
  • Pregnant or lactating women, premenopausal women without adequate contraception
  • Patient participating in other drug testing or participating in another drug test in the previous month

研究组 & 干预措施

Bronchoscopy with terlipressin administration

Experimental

Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

干预措施: bronchoscopy under local anesthesia (Procedure)

Bronchoscopy with terlipressin administration

Experimental

Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

干预措施: Biopsy sampling (Procedure)

Bronchoscopy without terlipressin administration

Placebo Comparator

Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration

干预措施: bronchoscopy under local anesthesia (Procedure)

Bronchoscopy without terlipressin administration

Placebo Comparator

Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration

干预措施: Biopsy sampling (Procedure)

Bronchoscopy with terlipressin administration

Experimental

Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration

干预措施: Terlipressin administration (Drug)

结局指标

主要结局

Number of biopsy realized during the endoscopy

时间窗: Day 1

The number of biopsy by endoscopy realized into each group will be calculated

次要结局

  • Number of biopsy allowing an histological diagnosis(Day 1)
  • Number of adverse events due to terlipressin administration(Day 1)

研究者

发起方
University Hospital, Rouen
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验